These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11487451)

  • 1. Hormone replacement therapy for prevention of coronary heart disease: current evidence.
    Khurana PS; Khurana C; Hsia J
    Curr Atheroscler Rep; 2001 Sep; 3(5):399-403. PubMed ID: 11487451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
    Hulley S; Furberg C; Barrett-Connor E; Cauley J; Grady D; Haskell W; Knopp R; Lowery M; Satterfield S; Schrott H; Vittinghoff E; Hunninghake D;
    JAMA; 2002 Jul; 288(1):58-66. PubMed ID: 12090863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
    Nevitt MC; Felson DT; Williams EN; Grady D
    Arthritis Rheum; 2001 Apr; 44(4):811-8. PubMed ID: 11315920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
    Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB
    JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
    Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vittinghoff E; Wenger N;
    JAMA; 2002 Jul; 288(1):49-57. PubMed ID: 12090862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.
    Simon JA; Hunninghake DB; Agarwal SK; Lin F; Cauley JA; Ireland CC; Pickar JH
    Ann Intern Med; 2001 Oct; 135(7):493-501. PubMed ID: 11578152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
    Prentice RL; Manson JE; Langer RD; Anderson GL; Pettinger M; Jackson RD; Johnson KC; Kuller LH; Lane DS; Wactawski-Wende J; Brzyski R; Allison M; Ockene J; Sarto G; Rossouw JE
    Am J Epidemiol; 2009 Jul; 170(1):12-23. PubMed ID: 19468079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study.
    Herrington DM
    Ann Intern Med; 1999 Sep; 131(6):463-6. PubMed ID: 10498564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogens should not be initiated for the secondary prevention of coronary artery disease: a debate.
    Hulley S
    Can J Cardiol; 2000 Aug; 16 Suppl E():10E-12E. PubMed ID: 10906618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical European view of the HERS trial.
    Lauritzen C
    Maturitas; 1998 Nov; 31(1):15-9. PubMed ID: 10091200
    [No Abstract]   [Full Text] [Related]  

  • 14. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
    Simon JA; Lin F; Vittinghoff E; Bittner V;
    Ann Epidemiol; 2006 Feb; 16(2):138-45. PubMed ID: 16039873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study.
    Grady D; Yaffe K; Kristof M; Lin F; Richards C; Barrett-Connor E
    Am J Med; 2002 Nov; 113(7):543-8. PubMed ID: 12459399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen replacement therapy and the prevention of coronary heart disease in postmenopausal women.
    Contreras I; Parra D
    Am J Health Syst Pharm; 2000 Nov; 57(21):1963-8; quiz 1969-71. PubMed ID: 11094650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG; Herrington DM
    Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy (HRT) and ischaemic heart disease: getting to the heart of the matter.
    Chew S; Ng SC
    Singapore Med J; 2002 Jan; 43(1):41-4. PubMed ID: 12008777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.